 Home > Active Ingredient News > Antitumor Therapy > ESMO Open: Is Axitinib harmful to renal cell carcinoma?

ESMO Open: Is Axitinib harmful to renal cell carcinoma?

 Last Update: 2021-05-08
 Source: Internet
 Author: User

Tags

stable

non invasive cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Renal cell carcinoma (renal cancer for short) is a highly malignant tumor in the urinary system and one of the most common tumors.

The ATLAS trial, which evaluated the efficacy of adjuvant axitinib versus placebo for renal cell carcinoma (RCC), was stopped because the planned interim analysis indicated that it was invalid.

This article reports the results of the subgroup analysis of the trial by race, duration of treatment, dose adjustment, and toxicity.

DFS in high-risk patients

Neither Asian nor non-Asian people have observed a disease-free survival (DFS) benefit from axitinib or placebo treatment .

No disease-free survival (DFS) benefit was observed from either Asian or non-Asian treatment with Axitinib or placebo .

DFS in subgroup patients vs non-Asian patients

Compared with non-Asian patients, Asian patients treated with Axitinib had a higher proportion of invoking drug doses due to adverse reactions (AE) (58.

In Asian patients, proteinuria, hypothyroidism, nasopharyngitis, and hypertension are more common in Japanese patients than in Korean patients, and more common in Korean patients than in Chinese patients .

Proteinuria, hypothyroidism, nasopharyngitis and hypertension are more common in Japanese patients than in Korean patients, and more common in Korean patients than in Chinese patients

DFS in patients with reduced dose of axitinib vs.

Compared with patients treated with a stable dose of Axitinib, patients with a dose reduction had a longer DFS Compared with patients treated with a stable dose of Axitinib, patients with a dose reduction had a longer DFS

In summary, the subgroup analysis of Asian patients vs.

The duration of treatment does not affect DFS.

Original source:

Quinn DI,Ng CF,Grande E et al.

org/10.
1016/j.
esmoop.
2021.
100105" target="_blank" rel="noopener">ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.